title: Chemotherapy of advanced seminoma: clinical significance of radiological findings before and after treatment.
abstract: The predictive significance of the mass detected following chemotherapy was assessed in 46 patients with advanced seminoma. Patients with residual viable seminoma in the post-chemotherapy operation specimen or who developed recurrent disease were regarded as chemotherapy failures. This group included 1 of 20 patients in whom the retroperitoneal masses were less than or equal to 10 cm2 3 to 4 weeks after chemotherapy and 4 of 15 patients whose residual masses were greater than 10 cm2. Four of 11 patients with mediastinal tumours achieved a complete remission (mediastinal masses less than or equal to 1 cm2). However, 2 of these 4 patients relapsed, as did 2 of the 4 who achieved a partial remission. In no case was the original size of the tumour significantly related to treatment failure. Three patients had residual lung masses; 1 of these contained histological evidence of viable tumour. In one-third of the irradiated relapse-free patients, slightly enlarged masses were visible on follow-up computed tomography scans taken several years after treatment, even in patients without tumour activity. There is a 25% risk of relapse in patients with advanced seminoma who have retroperitoneal masses greater than 10 cm2 following cisplatin-based chemotherapy. They should be followed up regularly for many years.
authors.affiliation: Department of Medical Oncology, Norwegian Radium Hospital, Oslo, Norway.
authors.forename: S D
authors.initials: SD
authors.lastname: Fosså
authors.forename: G
authors.initials: G
authors.lastname: Kullmann
authors.forename: H H
authors.initials: HH
authors.lastname: Lien
authors.forename: A E
authors.initials: AE
authors.lastname: Stenwig
authors.forename: S
authors.initials: S
authors.lastname: Ous
mesh_terms: D000328:Adult; D002945:Cisplatin / Q000627:therapeutic use; D003131:Combined Modality Therapy; D004407:Dysgerminoma / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology / Q000628:therapy; D006801:Humans; D008113:Liver Neoplasms / Q000556:secondary; D008175:Lung Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology / Q000628:therapy; D008297:Male; D008479:Mediastinal Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology / Q000628:therapy; D009364:Neoplasm Recurrence, Local; D011237:Predictive Value of Tests; D012186:Retroperitoneal Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology / Q000628:therapy; D012189:Retrospective Studies; D014057:Tomography, X-Ray Computed
chemical_list: D002945:Cisplatin